Novo Nordisk (NVO) Slides After CEO Departure; Analyst Flags Deeper Strategic Concerns
Novo Nordisk (NVO, Financials) shares fell nearly 4% after the company said CEO Lars Fruergaard Jrgensen will step down. A replacement has not been named.
Warning! GuruFocus has detected 1 Warning Sign with NVO.
Shares of the Ozempic maker have declined 52% over the past year, compared with a less than 3% drop for rival Eli Lilly (LLY, Financials), which markets the weight-loss drug Zepbound.
Novo's leadership change comes amid mounting pressure in the GLP-1 drug space, where Lilly's prescription growth has outpaced Novo's performance.
Evan David Seigerman of BMO Capital Markets told CNBC the leadership change won't resolve the company's core strategic issues. He said the company must reevaluate its current trajectory and design a more effective long-term plan.
Seigerman's remarks fueled speculation that Novo could pursue acquisitions. Shares of Structure Therapeutics, which is developing oral obesity drugs, rose more than 2% at midday on takeover rumors.
Explore Novo Nordisk's historical financials.
Track insider trades at Novo Nordisk.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk Novo Nordisk won't stop taking action to protect Americans from the dangers of illicit foreign active pharmaceutical ingredients in knock-off drugs Efforts will continue to make authentic, FDA-approved Wegovy® directly available through NovoCare® Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients living with chronic diseases PLAINSBORO, N.J., June 23, 2025 /PRNewswire/ -- Novo Nordisk announced today that the company will no longer be working with Hims & Hers Health, Inc., and that direct access to Wegovy® will no longer be available to Hims & Hers Health, Inc. via NovoCare® Pharmacy. In late April, the FDA resolved the Wegovy® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy® through NovoCare® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of "personalization" and are disseminating deceptive marketing that put patient safety at risk. "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy®," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. "We will work with telehealth companies to provide direct access to Wegovy® that share our commitment to patient safety – and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action." Novo Nordisk is deeply concerned and is continuing to take proactive measures to keep US patients safe from knock-off drugs made with foreign illicit active pharmaceutical ingredients. Based on Novo Nordisk's investigation, the "semaglutide" active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China. According to a report from the Brookings Institute, FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide, nor has FDA ever reviewed or authorized the quality of the "semaglutide" they produce. The report also found that a "large share of [these Chinese suppliers] were never inspected by FDA, and many of those that were [inspected] had drug quality assurance violations." US patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients. More information can be found on About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.1-3 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.2,3 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.4,5 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.6,7 In the US, about 40% of adults live with obesity.8 About NovoCare® Pharmacy NovoCare® Pharmacy provides cash-paying patients who have been prescribed Wegovy® with the ability to schedule shipments of their Wegovy® prescriptions directly to their home. Beyond convenient home delivery, NovoCare® also supports patients with benefit verification, refill reminders, and access to live support from a NovoCare® case manager. More information about NovoCare® Pharmacy is available at NovoCare® pharmacy | NovoCare®. About Wegovy® (semaglutide) injection 2.4 mg What is Wegovy®? WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity: to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off. Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. It is not known if Wegovy® is safe and effective for use in children under 12 years of age. Important Safety Information What is the most important information I should know about Wegovy®? Wegovy® may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Do not use Wegovy® if: you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy® Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes into your breast milk Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly. What are the possible side effects of Wegovy®? Wegovy® may cause serious side effects, including: inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back gallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away. serious allergic reactions. Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy® increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. Please see Medication Guide and Prescribing Information, including Boxed Warning, for Wegovy® at About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US) +1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global) +45 3079 6656 azey@ Ida Schaap Melvold (Global) +45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References: 1. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. 2. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. 3. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. 4. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: 5. World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: 6. Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: June 2025. Available at: 7. Centers for Disease Control and Prevention. Why it matters. Last accessed: June 2025. Available at: 8. Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed June 2025. Available at: View original content to download multimedia: SOURCE NOVO NORDISK INC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
an hour ago
- CNBC
Stocks making the biggest moves premarket: Tesla, Northern Trust, DoorDash, Northrop Grumman, Exxon Mobil and more
Check out the companies making headlines before the bell. Northern Trust – Shares rose more than 6% after the Wall Street Journal, citing people familiar with the matter, reported that Bank of New York Mellon approached Northern Trust last week to convey interest in a merger between the two rivals. The report also said that BNY is considering its next steps, which could include a formal bid to Northern Trust. However, the people cautioned that the talks might not result in a deal. Fiserv — Shares of the financial services firm jumped almost 5% after it revealed plans to broaden its presence in the stablecoin space. The company plans to launch a stablecoin and digital-asset platform for banking clients. It also stuck partnerships with Circle and Paypal to further these efforts. Circle shares were up 5%, while Paypal gained almost 1%. Novo Nordisk – The pharmaceutical stock plummeted more than 5% after the latest results for the company's next-generation obesity drug CagriSema were disappointing and suggested no clear advantage over Eli Lilly's Zepbound. The company also announced that it has ended its collaboration with Hims & Hers Health , citing compounding and marketing concerns. Hims shares fell about 20%. Estee Lauder – The cosmetics stock popped 2% on the back of Deutsche Bank's upgrade to buy from hold. The bank now has the highest price target on Wall Street of analysts polled by LSEG. DoorDash – The food delivery company moved 2% higher. Raymond James upgraded the stock to strong buy from outperform. The firm said the synergy potential with British food delivery service Deliveroo, which DoorDash is acquiring, is underappreciated. Energy stocks – Shares of energy companies were higher after Iran's parliament backed closing the Strait of Hormuz , a key trade route for crude oil. The U.S. has since called on China to prevent Iran from closing the route. Exxon Mobil rose nearly 2%, while Marathon Petroleum and ConocoPhillips each advanced more than 1%. Others linked to nuclear energy like Centrus Energy and Uranium Energy Corp. also gained more than 3% and 1%, respectively. Tesla — Shares gained nearly 1%, after Tesla rolled out its robotaxi service in Austin, Texas, over the weekend. Wedbush analyst Dan Ives said a ride in the taxi exceeded his expectations . RTX , Northrop Grumman , Kratos Defense and Security – Defense stocks ticked higher on Monday after the United States struck Iranian nuclear facilities. Shares of RTX and Northrop Grumman each added around 1%. Military tech stock Kratos gained 2%. — CNBC's Alex Harring, Jesse Pound, Sarah Min, Christina Cheddar Berk and Michelle Fox contributed reporting.
CNBC
an hour ago
- CNBC
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Novo Nordisk on Monday said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. Shares of Hims & Hers fell about 20% in premarket trading Monday. Novo Nordisk in April said it would offer Wegovy through several telehealth companies such as Hims & Hers to expand access to the blockbuster injection now that it is no longer in short supply in the U.S. The end of the Wegovy shortage meant compounding pharmacies were legally restricted from making and selling cheaper, unapproved versions of Wegovy – with rare exceptions. Telehealth companies have said patients may still need personalized compounded versions of Wegovy due to medically necessary reasons, such as having allergies to certain ingredients in the branded product. But Novo Nordisk on Monday said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization. The drugmaker also accused Hims & Hers of "deceptive" marketing that is putting patient safety at risk. A Hims & Hers spokesperson did not immediately respond to CNBC's request to comment.
